Abbott has agreed to pay $385 million to resolve investigations and lawsuits related to its 2022 recall of powdered infant formula from its Sturgis, Michigan facility. The settlement does not imply any fault or liability, and the US government has closed its criminal investigation. Tests showed no unopened Abbott formula tested positive for Cronobacter sakazakii, a bacterium linked to infant illnesses. The CDC found no definitive link between the Sturgis plant and the reported cases, emphasizing contamination often occurs in homes. Abbott remains committed to product safety and serving families.
Medtronic and Abbott are both strong dividend-paying medical device companies, but Medtronic currently offers a higher dividend yield of 3.11% and stronger near-term growth prospects, including accelerating revenue and a planned diabetes business sep...
Investors in the Schwab U.S. Dividend Equity ETF (SCHD) who reinvested dividends over the past decade earned about $1.03 million from a $300,000 investment, trailing the S&P 500 index's $1.25 million by over $216,000. Despite a low expense ratio of 0...
